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Dynamics of erythropoiesis following renal transplantation. We exam-
ined the temporal dynamics of the correction of anemia following renal
transplantation in 65 recipients using a sensitive radioimmunoassay for
erythropoietin to determine the effects of modern immunosuppressive
agents, delayed graft function, and early acute rejection. Pretransplant
mean erythropoietin (25.6 3.3 mU/mi) was only 25% of the expected
value at the mean hematocrit of 27.2 0.7, and erythropoietin
correlated positively with hematocrit (r = 0.37, P < 0.05). Following
onset of graft function, erythropoietin increased to 109 13 mU/mi and
then decreased in a negative feedback fashion over the next several
months. Delayed graft function was associated with delay in the
assumption of this orderly process irrespective of the immunosuppres-
sive regimen used. Cyclosporine A produced a biphasic response
despite delayed graft function in recipients with underlying adult
polycystic kidney disease. Correction of anemia required resumption of
graft function. Onset of acute graft rejection within the first month
posttransplantation (14 episodes in 11 patients) abrogated the hemato-
poietic response until the rejection was successfully reversed, We
conclude that a major cause for the anemia of renal failure is subnormal
production of erythropoietin. Following transplantation, anemia cor-
rects in an orderly manner with restoration of the normal biofeedback
process between erythropoietin and red cell mass. This process is
delayed by failure of graft to function initially and interrupted by acute
early rejection, re-commencing following successful reversal.
The anemia of chronic renal failure results from several
interactive processes, chief among these being inadequate
erythropoietin production relative to the degree of anemia. In
addition, roles have been proposed for uremic inhibitors,
hemolysis and blood loss. Earlier studies have shown that
successful renal transplantation leads to correction of this
anemia over a three month or longer period [1—5]. With imme-
diate renal function, reticulocytosis begins early, at about a
week, and is preceded by an increase in erythropoietin produc-
tion [3—5]. These studies, however, have been limited by the
insensitivity of the erythropoietin measurement methods used
as well as by the number of subjects studied. Neither the effects
of delayed graft function nor the effects of the newer im-
munosuppression agents on the hematopoietic process has been
fully evaluated. In a previous report, we examined changes in
hematocrit, reticulocyte count, and serum creatinine in 102
patients who received renal grafts. We noted that reticulocyto-
sis occurs earlier in patients receiving cyclosporine A immuno-
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suppression compared to those receiving more conventional
therapy with azathioprine [6]. However, this earlier reticulo-
cytosis was not sustained and the rate of correction of anemia
was slower than in recipiens treated with conventional im-
munosuppressive regimens. The ultimate degree of correction
of the anemia was limited by the level of graft function attained.
Erythropoietin levels were available in only five of the patients.
The current study was performed to define the temporal course
of erythropoietin titers after transplantation using a sensitive
radioimmunoassay [7] and the influence of the above post-
transplant factors on erythropoiesis.
Methods
Study patients
Informed consent for the current study was obtained from
143 recipients of renal grafts between July 1, 1983, and Septem-
ber 10, 1985. All but one individual were over 18 years of age.
Only one pediatric kidney was implanted during this time
period. Serial changes in creatinine, hematocnt, and reticulo-
cyte count in 102 of these patients have previously been
reported [6]. At that time, however, data on serial erythropoi-
etin levels was available on only five patients and only in the
case of immediate graft function. No specific exclusion criteria
was used for entry into the current study aside from excluding
those patients known to be positive for hepatitis B antigen (13
patients) in order to minimize the hazards of transmission to
non-medical personnel. Two patients with antibody to HBAg
but no clinical or laboratory evidence of liver disease were
included. The only requirement for inclusion into the current
study was the pre-transplant availability of a complete blood
count, reticulocyte count, and a properly collected and proc-
essed tube for erythropoietin assay so that post-transplant
changes in these variables could be referenced to an initial
value. The most common reason for exclusion in the remaining
130 recipients was the failure to obtain and/or properly process
the baseline erythropoietin sample within one hour of collec-
tion. Data on an additional six patients were excluded because
they required a major surgical procedure within the first month
of transplantation.
All necessary pre-transpiant parameters were available in 65
recipients, representing 50 percent of eligible and 45 percent of
all renal transplants performed during this time period. Four of
the 65 patients were anephric. The current study population
consisted of 12 living—related (LR) and 53 cadaver—donor (CD)
recipients. Eleven of the 12 LR and 41 of the 53 CD recipients
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were part of our previous reported study [61. The current
sample of patients represents 60 and 44 percent, respectively, of
all LR and CD transplants performed during the 25.3 month
period and can be considered in part to be a sub-sample of our
previous study. Transfusions were avoided unless acute blood
loss developed or the patient became symptomatic at a hema-
tocrit less than 18 percent. Twenty of the recipients did not
receive any transfusions. The remaining 41 patients received
1.6 0.2 units of packed red cells in the pen-operative period.
Only 12 received an average of 1.3 0.2 transfusions post-
operatively, invariably during the first two weeks during a
period of initial graft dysfunction.
Study protocol
Erythropoietin levels and hematologic parameters were mea-
sured initially and remeasured at intervals of three to five days
in the early post-transplant period (first month) and at longer
intervals thereafter. Sequential data were available beyond the
first post-transplant month in 53 patients. Twelve patients had
graft failure within the first month. In four of these, graft loss
resulted from primary nonfunction. The remaining eight had
initial oligunc, graft renal failure followed by some graft func-
tion, but with onset of irreversible rejection were unresponsive
to treatment. Five of these patients had serum creatinines
decreasing to less than 4 mg/dl at the onset of acute severe
rejection whereas the other three had creatinines greater than
4.0 mgldl at the onset of rejection. The diagnosis of graft
rejection was made on the basis of previously reported criteria
[8] and included clinical variables (urine output, change in
serum creatinine), changes in renal blood flow (technitium
DP1'A and hippuran scans), ultrasound studies to exclude
obstruction and response to treatment. Renal biopsy was used
when the above criteria were insufficient for diagnosis, partic-
ularly in patients receiving cyclosporine A immunosuppression
and having poor graft function.
Laboratory methods
The complete blood count was measured by conventional
automated techniques, the reticulocyte count by counting 1000
cells after methylene blue staining, and the plasma erythropoi-
etin by using a radioimmunoassay (RIA-EPO) as described
previously [71. The red cell production rate pre- and post-
transplant was estimated from the normalized reticulocyte
count and the reticulocyte index. The normalized reticulocyte
count corrected the reported reticulocyte count for the number
of red blood cells with the hematocrit. The reticulocyte index
further normalized this by correcting for the premature release
of reticulocytes by a stimulated marrow. A reticulocyte index of
1 is the basal production necessary to maintain a normal
hematocrit. The calculations were performed using the method
of Hillman and Finch [9].
EDTA-plasma for RIA-EPO measurements was separated
from cells within one hour and then stored at —20°C until
thawed for assay. The antibody used in the RIA recognized
both asialated and sialated forms of erythropoietin. The mean
binding of the '251-erythropoietin to antibody was 18 2%.
Both serial dilutions of samples with levels greater than 125
mU/ml as well as additions of known amounts of purified
erythropoietin to unknowns (recovery experiments) were per-
formed with normal and uremic plasma to exclude factors
affecting binding of erythropoietin to the antibody. No effect of
uremic sera on binding was noted. Whenever possible, samples
from any given patient were measured within a single assay to
reduce interassay variation. The interassay coefficient of vari-
ation for pooled normal human serum was 24% (mean
erythropoietin 12.2 0.6 mU/mi) and 22% for nonrenal, mildly
anemic individuals (mean erythropoietin of 71.3 2.8 mU/mi).
Sera from selected transplant patients were run in the various
assays with a coefficient of variation of 12%. The intra-assay
coefficient of variation was 11.1 2.4%. The methodology for
the bioassay has been previously reported [10].
Immunosuppression
Conventional immunosuppression therapy, started immedi-
ately post-implantation, consisted of azathioprine plus predni-
sone, and was given to all 12 living—related recipients. Azathi-
oprine was given in a maintenance dose of 1.5 to 2.0 mg/kg
while prednisone was tapered from 60 to 20 mg/day within the
first six months. Thirteen cadaver—donor recipients were
treated with antilymphoblast globulin (ALG), 14 consecutive 20
to 30 mg/kg doses commencing on the day of transplantation, in
addition to azathioprine and prednisone. Prednisone was ta-
pered more slowly than in the LR recipients. The remaining 38
cadaver—donor recipients received cyclosporine A (CsA) and
prednisone, the latter tapered more rapidly than in ALG-treated
patients (to 20 mg/day on the fifth post-transplant day).
Cyclosporine A in the early post-transplant period was initially
administered to the first 22 patients in this subgroup at a dosage
of 14 mg/kg/day. Due to adverse effects of this dosage on grafts
with early graft dysfunction [11], it was subsequently lowered
to 7 to 10 mg/kg/day until the presence or absence of acute renal
graft failure (ATN) could be determined. Those with "acute
tubular necrosis" ATN were maintained on 7 mg/kg/day until
the graft recovered function, whereas those with immediate
function received 12 to 14 mg/kg/day. In the later post-transpla-
ntation periods cyclosporine was administered at dosages re-
quired to maintain a plasma cyclosporine level of 60 to 200
ng/ml (about 3 to 5 mg/kg/day). The various immunosuppres-
sion regiments were used concurrently in part until the superi-
ority of cyclosporine A in cadaveric grafts in our transplant
program was established [11]. Thus, LR recipients spanned the
entire study period of 26 months. ALG treated CD recipients
were studied during the first 18 months and cyclosporine during
the last 23.3 months.
Data analysis
Hematologic as well as RIA-EPO data during periods of acute
rejection were excluded from analysis of temporal profiles and
analyzed separately to determine the effect of rejection on
parameters of hematopoiesis. All results are given as the mean
SEM. When appropriate, pre-transpiant and post-transplant
data were compared by paired or unpaired Student's t-tests.
RIA-EPO results were not normally distributed and logarithmic
transformation was performed in some instances prior to sta-
tistical comparisons. ANOVA was used to compare results
among subgroups, followed by a Neuman—Kuels multiple group
comparison, if appropriate. Correlation between two or more
variables was determined by least squares regression. Differ-
ences in the slopes of regression equations were evaluated by
analysis of covariance. A probability value less than 0.05 was
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Table 1. Distribution of disease states among the 3 major
pretransplant groups
Group
Disease state
APCKD HTNS CON DM IN Unknown
Living—related
Cadaver—donor
ALO-treated
Cadaver—donor
CsA-treated
1
1
12
1
4
7
7 2
5 3
8 5
1
0
5
0
0
3
Values in each cell represent number of subjects.
considered significant. Chi-square or Fisher's exact test was
used to determine differences in distributions.
Results
Demographics and patient subgroups
The patient population was heterogeneous with regard to
underlying cause of renal failure: 12 from hypertension, 20 from
chronic glomerulonephritis, 10 from diabetes mellitus, 14 from
polycystic kidney disease, 6 from interstitial nephritis, and 3 of
unclear etiology. Two of the latter as well as two APCKD
subjects had bilateral nephrectomies, all for recurrent infection.
The male/female ratio was 32:33. The age range varied from 17
to 66 with a mean of 38 2 (median 33). All LR recipients
experienced immediate graft function. Among cadaver—donor
recipients, 5 of 13 ALG-treated and 19 of 40 cyclosporine
A-treated patients developed delayed graft function. The period
of delayed graft function was significantly longer, 14.5 1.5
versus 8.6 1.0 days, in cyclosporine A than ALG treated
patients. The study population was thus divisible into 5 sub-
groups based on source of graft, immunosuppression regimen,
and the presence or absence of immediate graft function: (1) 12
live—related recipients on conventional therapy (azathioprine
and prednisone) with immediate graft function; (2) 8 cadaver
donor recipients receiving ALG plus conventional therapy with
immediate graft function; (3)5 cadaver-donor recipients receiv-
ing ALG plus conventional therapy with delayed graft function
(ATN); (4) 21 cadaver-donor recipients receiving CsA and
prednisone with immediate graft function; and (5) 19 cadav-
er-donor recipients receiving CsA and prednisone with delayed
graft function (ATN).
The distribution of disease entities among the three major
subgroups is given in Table 1. Chi-square analysis revealed no
differences in distribution of diseases among these three groups
(x2 = 13.7, df = 10, P = 0.18). However, when all other
diseases except APCKD were lumped together, there was a
significant excess of APCKD in the CsA-treated cadaver-
ic—donor recipients (P = 0.04). APCKD patients represent a
growing percentage of our transplant recipients (currently
25%). Of the 10 APCKD recipients who still had native kidneys
in situ, 9 received CsA immunosuppression. Seven of these had
delayed graft function.
Erythropoiesis
Overall changes. In nonrenal anemic patients, erythropoietin
increases exponentially with decreasing hematocrit as shown in
Figure 1 (modified from ref. 7). The patients in this figure
10 20 30 40 50 60
Hematocrit, volpercent
Fig. 1. Relationship of plasma erythropoietin levels to hematocrit in
non renal anemias (side cell, rheumatoid arthritis, hemolysis, simple
nutritional). The symbols represent both bioassay and RIA for eryth-
ropoietin as there is complete overlap between the two assays. Note the
inverse relationship between erythropoietin and hematocrit. The solid
line represents the least square regression for all erythropoietin values(N = 128), whereas the dotted lines represents the 95% confidence
limits.
Table 2. Hematopoietic indices among the immunosuppression
regiments
Hematocrit Erythropoietin Retic. index
Aza + P(12) 26.6 1.3 24.3 4.4 0.58 0.10
ALG + Aza + P (13) 27.9 1.0 25.9 3.3 0.51 0.08
CsA + P (40) 28.4 0.8 26.2 5.0 0.70 0.13
include patients with sickle cell anemia, rheumatoid arthritis,
hemolytic anemias, and simple nutritional (iron deficiency)
anemias. There is complete overlap between the bioassay and
RIA values of plasma or serum samples from these anemic
states. As hematocrit and therefore oxygen carrying capacity
decrease, erythropoietin increases exponentially, but the 95%
confidence limits for the range of EPO at any given hematocrit
was quite large, about 1.4 (base 10) orders of magnitude (or
22-fold) in both the bio- and immunoassay. The reason for this
wide biological dispersion is unknown, but is unlikely to result
from interassay or intra-assay variability since the calculated
effect from the sum of the 95% confidence limits for both inter-
and intra-assay effects is about 2.
There were no differences in the pre-transplant EPO or
hematocrit values among the three immunosuppression sub-
groups by analysis of variance (Table 2). Table 3 shows the
effect of disease etiology on the pre-transplant hematopoietic
indices. Recipients with tubulointerstitial disease and anephric
patients had significantly lower hematopoietic indices the other
subgroups. Maintenance of hematocrit in anephric patients
pretransplantation required transfusion. Mean hematocrits and
reticulocyte index (RI) within subgroups tended to vary directly
with erythropoietin.
Table 4 summarizes the hematologic and renal parameters of
the population prior to and at the last available post-transplant
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All results mean SEM. There were no differences in pretransplant
indices.
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indices
Disease state
APCKD HTNS CON DM IN Anephric
(12) (12) (20) (10) (6) (4)
Hematocrit 30.8
2.1
28,2
1.5
27.5
1.0
26.3
1.6
23.4
1.4
19.7
1.1
Erythropoietin 44,8
14.8
25.6
3.0
20.8
2.2
24.6
6.0
18.4
2.0
6.6
1.6
Retic. index 0.94
0.22
0.80
0.20
0.54
0.08
0.68
0.08
0.32
0.06
0.15
0.02
All results mean SEM. Numbers in parenthesis represent number of
subjects. Two APCKD and 2 recipients with unknown etiology are
included in the anephric population. ANOVA followed by Neumann—
Kuels comparison showed that subjects with IN and those who were
anephric had significantly lower reticulocyte indices than the other 4
groups. Erythropoietin in anephric patients was significantly lower than
in IN recipients.
Pre
N=65
Posta
N=53
Erythropoietin mu/mI 25.6 3.3 35.3 3.6
Hematocrit vol% 27.2 0.8 40.8 0.9
Reticulocytes % 1.5 0.1 1.9 0.2
Normalized retic. % 1.0 0.1 1.7 0.2
Retic. index % 0.6 0.1 1.4 0.1
All results are mean SEM
a At a mean interval of 147 8 days (range 77 to 519)
date; this was a mean interval of 147 8 days post-transplan-
tation (range 77 to 519 days). The pre-transplant EPO level of
25.6 3.3 mU/mi was slightly, but significantly higher than that
of normal controls, 16 2 (N = 10). However, it was only
about one—fourth of the expected value, 100 mU/ml, at the
average pre-transplant hematocrit of 27.2 0.7%. Note that
both the uncorrected reticulocyte count and the normalized
count pre-transplant would be considered normal, whereas the
reticulocyte index shows that red—cell production rate was only
60% of normal. The mean value of the last RIA-EPO value
available, 35.3 3.6 mU/ml (Table 4), as well as the reticulo-
cyte indices obtained after an interval of 147 8 days, do differ
significantly from those pre-transpiant. In spite of incomplete
correction of anemia in some of the patients primarily due to
some degree of graft damage from rejection and/or cyclosporine
A toxicity, the mean hematocrit increased significantly from 27
to 41%, reflecting the increased blood production rate seen in
the normalized reticulocyte counts. The latter, having previ-
ously peaked, were returning toward normal.
Pre-transplant, using the entire population of 63 patients,
there was a significant linear positive correlation between EPO
and hematocrit: Log[EPO] =0.919 + 0.014 [Hct]; r = 0.37, P <
0.05 (Fig. 2). Normalized reticulocyte count in turn correlated
positively with EPO: N-Rtc% = 0.62 + 0.015[EPO]; r 0.63, P
<0.001.
There was a stronger correlation between EPO and hemato-
crit in the subset of patients with underlying polycystic kidney
disease and hypertensive nephrosclerosis (r = 0.64, P < 0.001,N = 23); these are shown by the closed symbols in Figure 2.
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Fig. 2. Relationship of plasma erythropoietin levels to hematocrit in
transplant recipients prior to transplantation. The two dashed lines
represent the 95% confidence limits for non-renal anemia. Note the
positive rather than the expected negative correlation in these renal
failure patients. Closed circles and triangles represent recipients with
APCKD and hypertensive nephrosclerosis respectively. Open symbols:
() anephric, (O') diabetic nephropathy, (0) CGN, and (V) interstitial
nephritis. The regression for the patients with APCKD and I-IN is given
by the relationship log[yJ = 0.60 = 0.O2Shct which apparently gives the
correlation for the entire group, logy 0.92 + 0.0l4[hct]. 65% (N = 42)
of the recipients had a subnormal level of EPO, 33% (N = 22) normal
levels, and only one patient an elevated level.
When the patients without hypertensive nephrosclerosis or
PCKD were analyzed separately, no correlation between
erythropoietin and hematocrit was noted, although the correla-
tion between reticulocyte count and EPO persisted. The posi-
tive correlation between hematocrit and EPO in renal failure
patients shown in Figure 2 was unexpected since EPO corre-
lated negatively with hematocnt in other nonrenal anemic states
(as indicated by the broken lines; 95% confidence limits from
Figure 1 are redrawn in this and Figure 3). Compared to
nonrenal anemic patients, 65% of the transplant recipients had
a subnormal pre-transpiant erythropoietin level for their degree
of anemia (< the 5% confidence level for nonrenal anemias),
33% fell within the normal or "appropriate" range, and one
individual had a value greater than the 95% confidence limit but
was not polycythemic.
Data for the late posttransplant period (greater than 2.5
months) is shown in Figure 3A. All data in this figure were taken
at least one month beyond any previous acute rejection epi-
sode. No correlation of hernatocrit with EPO was found.
Normalized reticulocyte percentage, however, continued to
depend on EPO in those individuals whose values fell within the
normal range: N-Rtc% = 1.05 + 0.013[EPO}; r = 0.58, P <
0.05.
Comparison of the pre- and post-transplant regressions of the
normalized reticulocyte percentage on EPO showed a signifi-
cant increase in intercept but not in slope. At these times
post-transplantation, the hematocrit varied inversely with the
reticulocyte count, with the latter approaching zero as hemato-
crit increased toward 53 vol%. At a hematocrit of 53% or
greater, levels of erythropoietin in normals became unmeasur-
able (Fig. 1).
In evaluating the distribution of RIA-EPO values after 2.5 or
more months post-transplantation, we noted that EPO titer in
Table 3. Effect of disease state on pretransplant hematopoietic
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Table 4. Effect of transplantation on hematopoietic indices
18 of 53 individuals that were outside the normal biofeedback
range (dotted lines in Fig. 3A) and appeared to cause the
apparent loss of normal biofeedback. Six of these 18 individuals
had no or mild anemia (hematocnts > 36%) prior to transplan-
tation and may represent continued disordered erythropoiesis
from their native kidneys [12]. No obvious explanation was
noted in the remaining seven patients, and measurements of red
cell mass would be required to exclude absolute or relative
increase in this value. No patients had an increase in platelets,
leukocyte count, or LAP level. All disease groups were repre-
sented by patients with increased erythropoietin for their hem-
atocrit, but the majority had CGN.
The relationship of erythropoietin level to renal function after
2.5 or more months is shown in Figure 3B. Some individuals
had significantly impaired renal function (serum creatinine >
3.0 mgldl). No relationship between the two variables was
apparent. Note that the creatinine levels tended to be greater in
those CsA patients with initial graft dysfunction than in the
other subgroups.
Figure 4 delineates the overall changes in erythropoiesis
following recovery of renal function. The top panel depicts the
pattern in a CD ALG-treated individual with immediate graft
function. In this recipient, an increase in RIA-EPO to about
twice basal levels preceded the rise in reticulocytes by several
days, which in turn was followed by a rise in hematocrit. Full
correction of anemia was blunted with hematocrit at a 35%
plateau due to the development of iron deficiency. This was
noted and then corrected at about three months post-transplant
with the hematocrit rising and the erythropoietin decreasing
into the normal range.
In the absence of early acute rejection, the early temporal
pattern for the hematopoietic values—first month—was gener-
ally followed by almost all recipients of grafts with immediate
function irrespective of source (living—related or cadav-
er—donor). The bottom panel shows a CD recipient treated with
an identical immunosuppression protocol who sustained initial
graft function. Note that, unlike the pattern in the top panel,
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erythropoiesis was delayed during the first two weeks while
dialysis was continued until the graft began to function. During
this period of "ATN" the patient required transfusion on two
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Fig. 3A. Distribution oferythropoietin levels in recipients greater titan 2.5 months post-transplantation (147 8 days). Eighteen of 38 patients
had elevated erythropoietin values (above the 95% confidence limit) but only 7 were truly erythrocytotic (hematocrit > 53% in men and 48% in
women). The remainder except for one had appropriate levels of erythropoietin. Anemic patients had evidence of renal insufficiency. B.
Relationship of erythropoietjn levels to renal function for the data in A. Both scales are logarithmic. LR conventionally—treated recipients are
denoted by triangles, CD ALG-treated recipients by circles and CSA-treated recipients by squares. Open symbols refer to the occurrence of
immediate graft function and closed symbols to delayed graft function (ATN) following implantation. Note that CsA-treated recipients with initial
graft dysfunction ultimately have higher creatinines than the other groups. There is no relationship between erythropoietin and serum creatinine.
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Fig. 4. Temporal relationships between the various hematopoietic
indices in an ALG-treated cadaver-donor (A) diabetic recipient with
immediate function, and an ALG-treated CD recipient with delayed
graft function (B). Note that the increase in erythropoietin precedes
changes in reticulocyte count with a further lag before the hematocrit
increases. A also shows incomplete correction of anemia when the
recipient developed iron deficiency. The arrows in B denoted by "T"
indicate packed red—blood cell transfusions. Symbols in A are: (A)
hematocrit, () erythropoietin, (•) reticulocytes, (') S. Symbols in B
are: (A) hematocrit, (•) EPO, (•) reticulocytes, () creatinine.
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occasions, denoted by the arrows. Erythropoietin levels and
reticulocyte counts began to rise during the "diuretic" phase of
ATN, and in this case the changes in reticulocytes appeared the
outstrip those in erythropoietin during this period. The time
phase between changes in erythropoietin and reticulocytes
during such rapid recovery of renal function frequently could
not be separated clearly since erythropoietin levels were not
measured daily.
Early changes in hematopoiesis. The early mean post-trans-
plantation changes in EPO for those recipients with immediate
function are summarized in upper panel of Figure 5. Because of
the large individual variability in EPO at a given hematocrit,
temporal data for each individual were normalized by the
corresponding pre-transplant value. In the absence of ATN,
erythropoietin increased significantly by the third post-trans-
plant day, rose to a plateau at a maximum between the 9th and
15th day, and then tended to decrease. The immunosuppression
regimen had no significantly detectable effect on the temporal
pattern, although the Epo levels tended to remain elevated
longer in cyclosporine treated patients. This effect in CsA
treated patients was dose dependent. Reticulocytosis devel-
oped earlier in cyclosporine A treated recipients receiving the
higher 14 to 15 mg/kg/day dosage, whereas the temporal pattern
of reticulocytosis in those who received lower CsA dosages
did not differ from that of live—related recipients receiving
azathioprine.
Delay in graft function (ATN) influenced this temporal pat-
tern during the first two to three weeks post-transplant (Fig. 5).
The data for all immediately functioning grafts irrespective of
immunosuppressive regimen is redrawn as IF-ALL for compar-
ative purposes. All five ALG-treated recipients having delayed
graft function showed no increase in RIA-EPO until renal
function commenced. RIA-EPO increased within three to eight
days following onset of diuresis and usually well before the
BUN or serum creatinine (Sr) reached their nadirs. The mean
BUN and Se,. were 48 and 3.6 mg/dl at the time of the increased
Epo levels (10 to 12 days). Thereafter, the same temporal
pattern was followed as observed in recipients of immedi-
ately—functioning grafts. By contrast, cyclosporine-A treated
recipients with delayed graft function as a group showed a
biphasic response, increasing initially for four to six days,
decreasing to pre-transpiant levels during continued ATN (7 to
15 days), then increasing with recovery of renal function. As
shown in Figure SC, the majority of cyclosporine-A treated
patients with ATN had a delay in erythropoietin production
similar to ALG-treated patients. The delay was longer due to
longer duration of graft dysfunction. The biphasic erythropoi-
etin response resulted from effects of cyclosporine A in some
individuals. The only apparent difference between the two
subgroups was the presence of in situ polycystic kidneys in
seven of eight of the recipients within the latter subgroup who
also received higher dosages of cyclosporine. Reticulocytosis,
however, although blunted and not sustained occurred earlier in
all cyclosporine-A treated recipients, just as in our previous
study [6], and its onset was independent of function or temporal
pattern of EPO. Of some interest, the reticulocytosis developed
despite the presence of a uremic state.
Intermediate and late erythropoiesis. The longer—term quan-
titative relationship between erythropoietin and hematocrit in
our recipients during periods of no rejection is shown in Figure
0 1-3 4-6 7-9 10-12 13-15 16-21
Days post-transplantation
Fig. 5. Effect of delayed graft function, immunosuppressive regimen,
and disease type on the early erythropoietin plasma response of
transplant recipients. Post-transplant values were normalized by each
individual's pre-transpiant level. A shows results in recipients whose
grafts functioned immediately. Despite normalization, the dispersion
was wide (saMs not shown) and there were no significant differences
among the three groups. B depicts the effect of delayed graft function
(ATN). The mean for all grafts with immediate function from A
(IF-ALL) is redrawn as the bold solid line. ALG-treated cadaver—donor
recipients with ATN showed a temporal delay of 9 days. By contrast
CsA-treated cadaver—donor recipients showed a biphasic response
despite an equal or longer duration of ATN. B demonstrates that the
biphasic phenomenon in C5A-recipients resulted from a marked in-
crease in erythropoietin in recipients primarily having polycystic kidney
disease (7/8) whereas the recipients with other diseases (11) behavedjust like the ALG-treated patients. Numbers in parenthesis reflect
number of erythropoietin measurements within each period.
6 where the normal feedback range (95% confidence limits for
assayable erythropoietin levels found in other anemias not
associated with chronic renal diseases) is also shown. During
the process of recovery from anemia of renal failure, temporal
changes in RIA-EPO and hematocrit in our renal transplant
patients are represented in Figure 6 by the solid line connecting
points from left to right. At each point the mean values
represent differing samples of patients from the total group of 63
patients.
Starting from an inappropriately low pre-transplant RIA-EPO
level of 26 mU/mI the overall temporal profile showed a
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Fig. 6. Temporal changes in mean erythropoietin levels in the entire
population in the absence of rejection episodes. The dotted lines
represent the 95% confidence limits for the biofeedback relationship in
nonrenal anemic individuals. The numbers in parentheses indicate the
number of subjects in whom erythropoietin was measured within each
period. Following transplantation the erythropoietin levels peak at a
mean of 16 1 days without a significant change in the hematocrit from
pre-transplant. The subsequent points represent differing samples from
the entire group of65 patients after3l 1,50 1,75 I and 109 2 days
post-transplantation. The relationship between hematocrit and erythro-
poietin past the peak is given by log [EPO] = 2.18 — 0.016 [Hct].
log[EPO] 2.18 — 0.016[hematocritj; r = 0.73 P < 0.001
or:
EPO = 109 — 1.72[Hct]; r = 0.613, P < 0.001, N 114.
It is of some note that changes in erythropoietin were indepen-
dent of time beyond the first post-transplantation month (co-
variance analysis) suggesting that individuals followed differing
temporal courses.
Effect of acute early rejection
Early acute rejection (first three weeks post-transplantation)
was studied in 11 patients. In all cases the diagnosis was made
by biopsy confirmation and/or an appropriate response to
therapy with pulse sterioids and/or high oral recycle. Cyclo-
sporine-A treated patients usually required a transient increase
in CsA dosage if rejection occurred in the presence of a
sub-optimal CsA level (<100 ng/ml). A typical clinical course is
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Fig. 7. Representative course in a recipient with a camel—back rejec-
tion. Note that the abscissa is not linear in scale. Note also that the
plasma erythropoietin levels and serum creatinine oscillate 180 degrees
out of phase with each other during the two periods of rejection
(increased plasma creatinine in A). B shows that the reticulocyte counts
followed the plasma erythropoietin levels and that full correction of
anemia was only achieved when long—term graft function was established.
shown in Figure 7. Note the suppression of EPO (A) and
reticulocytosis (B) even though rejection commencing on post-
transplant day 15 was "mild" with serum creatinine increasing
by 0.5 mg/dl to 1.8 mgldl. Despite initial control of the rejection
episode with a decrease in serum creatinine to 1.5 mg/dl, EPO
and reticulocytosis were only partially restored to pre-rejection
values. The presence of an incompletely treated rejection
manifested itself on day 30 (camelback—.creatinine rejection).
Only after successful reversal of this camelback rejection did
EPO increase and was reticulocytosis restored completely.
Mean results for all 11 patients with early rejection (14 separate
episodes) are shown in Figure 8. Prior to onset of such
rejections, good graft renal function had commenced (mean
serum creatinine 1.7 0.2 mg/dl). Erythropoietin had increased
2.5-fold to 66 7 mU/ml, and erythropoiesis stimulated as
evidenced by the reticulocyte percentage of 4.4 0.3% (retic-
ulocyte index 1.7 0.2). The reticulocyte index correlated
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biofeedback pattern in the absence of acute early rejection. A
measured maximal level of EPO-RIA of 109 13 mU/mi
occurred after a mean interval of 16 1 (range 5 to 32 days).
The peak EPO level was generally reached earlier in recipients
having good early graft function. At this post-transplant time no
significant change in hematocrit from pre-transplantation had
occurred, but most recipients were exhibiting good renal gtaft
function or recovering from ATN. The mean maximal plasma
erythropoietin level was more than fourfold greater than at
pre-transpiantation, and totally appropriate for the prevailing
level of anemia. Thereafter, as the average hematocrit of the
sample population increased, plasma RIA-EPO measured at
varying monthly intervals progressively decreased. The de-
scending portion of the curve as the relationship:
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During
Rejection
Fig. 8. Effect of acute early rejection in 11 recipients (14 separate
events). Rejection suppresses erythropoietic indices which recover
after 16 days following successful treatment.
positively with EPO at this time (RI = 0.98 + 0.11 EPO, r
0.67, P < 0.05). All indices were significantly depressed during
rejection, EPO to 17 2 mU/ml and reticulocyte count ot 2.8%
(reticulocyte index of 0.8 0.1) at a time that mean serum
creatinine had doubled to 3.4 0.4 mg/dl. The positive corre-
lation of the reticulocyte index to EPO was lost (RI = 0.87 —
0.005 EPO, r = 0.22, P <0.3). The disproportionate decrease in
EPO (threefold) compared to reticulocyte count (onefold) prob-
ably reflects the differences in the time constants for the two
processes, about four hours for the metabolic clearance of EPO
compared to days for the production and release of reticulo-
cytes into the circulation. Twelve to 16 days following success-
ful reversal of rejection at a time when steroid administration
had returned to prerejection amounts and mean serum creati-
nine to 2.3 0.3 mg/dl, erythropoietic indices were fully
restored (EPO to 92 14 mU/ml, reticulocyte index to 3.7
0.3) with the hematocrit rising. No correlation was noted
between the maximal increment in serum creatinine (range 0.5
to 3.8 mgldl) and changes in EPO and reticulocyte index.
Discussion
The anemia of chronic renal failure is multifactorial, and
currently only corrected by a successful renal transplant al-
though the imminent availability of recombinant erythropoietin
is likely to change this. Two recent studies have clearly
documented that recombinant erythropoietin given in appropri-
ate amounts is able to correct the anemia of dialysis patients
[13, 14], but its general availability may still require a year or
more. Several earlier studies demonstrated that post-transplan-
tation erythropoietin increased to detectable limits in about half
to two—thirds of recipients with graft function [3—5]. These early
studies were limited by the insensitivity of the assays used.
Subsequent studies focused on post-transplant erythrocytosis
in which erythrocythemia occurred [1, 2]. The studies of
Dagher et al [12] and Thevenod et a! [2] indicated that the
transplanted kidney worked within the normal feedback regu-
lation range, but that erythrocytosis resulted from increased
disordered release of erythropoietin from native kidneys.
This paper focuses on and describes the temporal correction
of the anemia of chronic renal failure, particularly with respect
to the effects of preceding delayed graft function, acute graft
rejection, and the newer immunosuppressive agents. The radio-
immunoassay used to measure erythropoietin in specific with a
detection limit of 1 to 4 mU/ml. As a group, the recipients have
an average erythropoietin level pretranspiantation greater than
that present in normal individuals, results similar to those found
previously by Caro et al [15, 16] Radtke et al [17], and
McGonigle et al [181 using in vivo, in vitro, and radioimmuno-
assay methods, respectively. Since anephric patients had val-
ues barely greater than detection limits, the kidney appeared to
be the major site of production in uremic patients as well as
normal individuals. The erythropoietin levels, although ele-
vated compared to normal individuals without anemia, were
significantly lower, only 25% of the levels in nonazotemic
patients with similar degrees of anemia. Thus, inadequate total
production of erythropoietin by the native diseased kidneys
relative to the need is a primary factor for the anemia of chronic
renal failure. Relative to the actual "nephron mass" present in
end—stage renal failure, erythropoietin production by diseased
kidneys may be significant, as illustrated by +of the patients in
this study with sufficient function to be considered "adequate".
The contribution of other factors to the anemia of renal
failure can only be qualitatively evaluated. In our pre-transplant
population there was a positive correlation between EPO and
hematocrit, engendered evidently primarily by those patients
with underlying adult polycystic—kidney-disease and hyperten-
sive nephrosclerosis. Such trends have not previously been
described in chronic renal failure patients in general [18] or in
polycystic kidney disease patients specifically [19]. In a study of
erythropoietin levels of nephnc patients in our chronic hemo-
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dialysis unit we were unable to note a significant correlation
betwen EPO and hematocrit (N = 74, unpublished observa-
tions). In part this may be the result of a relative paucity of
patients with hypertensive nephrosclerosis and PCKD remain-
ing within our own dialysis—patient pool (depleted by transplan-
tation), differences in length on dialysis (longer), and age (older)
compared to the transplanted patients. Similar or other factors
may be responsible for the lack of an observable correlation in
the other two cited studies [18, 19]. The positive correlation of
Epo to hematocrit in a subset of patients indicates a disordered
mechanism for EPO production in some patients not responsive
to normal physiological homeostatic mechanisms. The positive
correlation of reticulocyte count to erythropoietin in the entire
group, however, does indicate that erythropoietin stimulates
the bone marrow during uremia and predicts the successful use
of exogenously administered erythropoietin for the treatment of
this anemia. However, the correlation of erythropoietin and
hematocrit pre-transplantation only accounts for 40 of the
variance and suggest important contributions of other factors,
such as bone marrow resistance to erythropoietin in a uremic
mileau.
Studies in a uremic sheep model showed that the infusion of
erythropoietin—rich plasma restored hematocnts to normal
without any detectable inhibition on the action of erythropoietin
[201. In vitro studies, however, do indicate that uremic sera
contains substances capable of inhibiting bone marrow cells
from producing erythrocytes in response to erythropoietin
[2 1—231. The issue in question is the extent to which such
inhibitors are physiologically important. As illustrated in Figure
4, the rate of change in reticulocytes in some cases was greater
than that of erythropoietin during a rapid transition from the
"uremic" to the "normal" state. Until the steady state amounts
of erythropoietin needed to maintain normal hematocrits in
dialysis patients can be directly compared to production rates
(less differences in metabolic clearances) in normal and anemic
nonrenal patients, the role of "uremic inhibitors" and other
factors enumerated previously can not be quantitated.
All transplanted patients except one had at least a twofold
increase in erythropoietin once graft function commenced.
Erythropoietin levels were not affected by the administered
packed cell transfusions for a number of reasons. First, there
was no correlation between the erythropoietin levels and the
amount of timing of any administered blood transfusions. This
would be expected since normal, pooled human plasma has a
erythropoietin concentration less than the average pre-trans-
plant value of uremic patients, and packed red—blood cells are
in addition plasma—poor. Secondly, the temporal sequence
typically consisted of a fourfold increase in erythropoietin
levels within the first two weeks from onset of diuresis, fol-
lowed by a slow but highly variable decrease in levels over the
next three months as the anemia was corrected. The majority of
transfusions were given intraoperatively and erythropoietin
levels post-operatively in transfused patients did not differ from
those given pre-operatively. Post-operative transfusions were
used sparingly and primarily in those patients with ATN who
required prolonged dialysis, a state characterized by continued
"low" erythropoietin levels (Fig. 4). Delayed graft function in
ALG-treated recipients appeared to merely shift the phase of
the response by one to two weeks until function recovered.
Thus a burst in Epo production by the new functioning graft
heralded the correction of the anemia. In of the patients
normal feedback regulation ultimately developed. Our results
are quite similar but more extensive than those described by
Rejman et al [24] who studied a total of eight patients on
conventional immunosuppressives. The temporal course of
plasma erythropoietin levels is unlikely to have been signifi-
cantly affected by variable degrees of proteinuria present in our
patients. Clearance of erythropoietin, a 39,000 dalton glycopro-
tein, is estimated at 0.1 to 0.5 mllmin [25] but we did not
specifically evaluate this aspect. Complicating any evaluation
(in an unsteady state) of the effect of proteinuria and conse-
quent urinary losses of erythropoietinon by glomerular filtration
is the intrarenal site of production of this hormone. One would
have to first show that urinary EPO was not primarily derived
from such an intrarenal production site.
In some of our patients, erythropoietin rose as early as the
first to third post-transplant day, and in some cases reticulocy-
tosis occurred before complete correction of the uremic or
azotemic environment by the functioning graft was achieved.
This was easier to discern in ALG or cyclosporine-A treated,
cadaver—donor graft recipients whose grafts did not usually
achieve normal renal function as quickly as those of live—related
recipients. The lag phase between increases in erythropoietin
levels and onset of reticulocytosis in non-cyclosporine-A
treated patients ranged from two to nine days, and appeared to
occur earlier the greater the increment in EPO, although a
formal mathematical analysis was not attempted. Comparison
of the normalized reticulocyte counts at equal levels of EPO in
the same individuals before and after transplantation clearly
indicated higher rates of red cell production after transplanta-
tion. Whether or not this resulted from the removal of putative
uremic inhibitors of erythropoiesis [2 1—23] by the functioning
graft or the correction of other factors, such as hemolysis, could
not be determined.
As suggested by data from two of the patients in the series
of Rejman et al [24], this orderly biofeedback pattern of
erythropoiesis was interrupted by onset of acute graft rejection.
In all 14 episodes occurring in the early post-transplant period
during which frequent sampling was conducted, erythropoiesis
was dramatically abrogated for the duration of the rejection,
recovering only with successful reversal of the rejection. Over-
all plasma erythropoietin fell from 66 to 17 mU/ml at the height
of the rejection process. The degree of reduction of GFR cannot
be estimated directly from the serum creatinine levels in an
unsteady state [261. In several cases of mild and easily reversed
rejection, significant azotemia did not develop and no correla-
tion was noted in the 14 episodes studied between changes in
maximum serum creatinine and magnitude of change in hema-
topoietic indices. This suggests that retention of uremic "tox-
ins" did not cause the arrest of erythropoiesis but that it either
resulted from products generated by the rejection process or
from the suppression of EPO synthesis, Favoring the latter was
the loss in correlation between reticulocyte index and EPO
during rejection without a change in the intercept. Although the
data in chronic rejection was not analyzed formally, chronic
graft rejection or cyclosporine toxicity leading to varying de-
grees of renal insufficiency was associated with appropriate
degrees of anemia.
Of 53 patients who were sequentially followed for more than
2.5 months, 18 stabilized at erythropoietin levels greater than
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normal for the prevailing hematocrit but only seven (13%)
patients ultimately developed erythrocytosis. Transient erythro-
cytosis was noted in five of the remaining nine, two of whom
had evidence of mild chronic rejection. The most common
original disease associated with secondary erythrocytosis was
chronic glomerulonephritis. In view of the normal physiologic
behavior of most transplanted grafts, the source of the "ex-
cess" EPO in some of the patients is most likely the native
kidneys [2, 12]. In others the erythrocytosis appears to be
relative due to contraction of the plasma volume (unpublished
observations).
The genesis of the earlier reticulocytosis noted in cyclo-
sporine-A treated recipients is still unclear. As in our previously
reported series, reticulocytes increased earlier than in the other
subgroups, particularly in those receiving the higher dosages. In
those who were treated with lower doses of cyclosporine, the
magnitude of reticulocytosis was comparable to that of conven-
tionally—treated recipients and was associated with more rapid
normalization of serum BUN and creatinine. Steady state
creatinines approached those found in LR or ALG-treated CD
recipients [8]. Since the erythropoietin response was quite
similar to that of conventionally—treated patients, we believe
that our earlier observations of a blunting of erythropoiesis in
this subgroup resulted from inferior renal function because of
the higher dosages of the immunosuppressive drug in the early
post-transplant period [8]. The cyclosporine—treated patients
with delayed, early graft function also had early erythropoiesis.
Erythropoietin, however, increased transiently primarily in
patients having polycystic kidneys, whereas for unknown rea-
sons the early reticulocytosis was shared by all patients.
In summary, the results of the present study clarify some
aspects of the anemia of chronic renal failure. The chief
abnormality is subnormal production of erythropoietin for the
degree of anemia by the native diseased kidneys although a role
for uremic inhibitors could be postulated. Therapeutic use of
erythropoietin will correct the anemia when sufficient amounts
become available for general use. In a small subset of patients
erythropoietin production pre-transplantation is sufficient to
permit maintenance of normal hematocrits. The disease entities
associated with near or normal hematocrits were limited to
chronic glomerulonephritis, polycystic kidneys, and nephro-
sclerosis. Post-transplantation, anemia was corrected in an
orderly manner once graft function commenced and was abro-
gated by acute graft rejection. This correction was preceded by
increasing titers of erythropoietin. Cyclosporine A immunosup-
pression had a two edged effect on the ultimate restoration of
red cell mass. Although reticulocytosis occurred earlier, even in
the presence of ATN, the nephrotoxic effects of cyclosporine
indirectly affected the degree of correction of anemia. An
optimal regimen is yet to be found, but we believe that a balance
between the immunosuppression and nephrotoxicity can be
achieved in most recipients.
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